Evidence map›Paper›PMID 39575892›Full record

ArticleJournal of receptor and signal transduction research2024

The cannabinoid CB

Aidong Qi, Xueqing Han, Marc Quitalig, Jessica Wu, Plamen P Christov, KyuOk Jeon, Somnath Jana, Kwangho Kim, Darren W Engers, Craig W Lindsley and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of receptor and signal transduction research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aidong QiDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Xueqing HanDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Marc QuitaligDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Jessica WuDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Plamen P ChristovVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
KyuOk JeonVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
Somnath JanaVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
Kwangho KimVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
Darren W EngersDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Craig W LindsleyDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Alice L RodriguezDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.
Colleen M NiswenderDepartment of Pharmacology and Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.

Funding

REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Discovery of mGlu receptor PAMs for treatment of schizophreniaR01MH119673 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2019 to 2023
$3.6M
NICHD NIH HHS P50 HD103537NIMH NIH HHS R01 MH062646NIMH NIH HHS R01 MH119673
6 · The paper itself

Abstract

Schizophrenia is a complex disease involving the dysregulation of numerous brain circuits and patients exhibit positive symptoms (hallucinations, delusions), negative symptoms (anhedonia), and cognitive impairments. We have shown that the antipsychotic efficacy of positive allosteric modulators (PAMs) of both the M

Indexed as

Receptor, Cannabinoid, CB2SchizophreniaAllosteric RegulationAnimalsAntipsychotic AgentsCHO CellsCricetulusHumansReceptor, Cannabinoid, CB1Antipsychotic AgentsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2allosteric modulatorassay developmentCannabinoid receptorsdopamine signalingschizophrenia

Identifiers

PMID39575892
PMCPMC11636628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.